Suscribirse

Expert Consensus on the Diagnosis and Management of Digoxin Toxicity - 18/12/24

Doi : 10.1016/j.amjmed.2024.08.018 
Jason B. Hack, MD a, Sue Wingate, RN, PhD b, Ron Zolty, MD c, Michael W. Rich, MD d, Paul J. Hauptman, MD e,
a Brody School of Medicine, East Carolina University, Greenville, Nc 
b Gaithersburg, Md 
c University of Nebraska Medical Center, Omaha, Ne 
d Washington University School of Medicine, St. Louis, Mo 
e University of Nevada, Reno School of Medicine, Reno, Nv 

Requests for reprints should be addressed to Paul J. Hauptman, MD, University of Nevada, Reno School of Medicine, 1664 North Virginia Street, MS0332, Reno, NV 89557, USA.University of NevadaReno School of Medicine1664 North Virginia StreetMS0332RenoNV89557USA

Abstract

While there has been a decline in the use of digoxin in patients with heart failure and atrial fibrillation, acute and chronic digoxin toxicity remains a significant clinical problem. Digoxin's narrow therapeutic window and nonspecific signs and symptoms of toxicity create clinical challenges and uncertainty around the diagnostic criteria of toxicity and responsive treatment choices for the bedside clinician. A systematic review of published literature on digoxin toxicity (34,587 publications over 6 decades, with 114 meeting inclusion criteria) was performed to develop 33 consensus statements on diagnostic and therapeutic approaches which were then evaluated through a modified Delphi process involving a panel of experts in cardiology, nursing, emergency medicine, and medical toxicology. The results demonstrate agreement about the need to consider time of ingestion and nature of the exposure (ie, acute, acute-on-chronic, chronic) and the use of digoxin immune Fab for life-threatening exposure to decrease risk of death. While several areas of continued uncertainty were identified, this work offers formalized guidance that may help providers better manage this persistent clinical challenge.

El texto completo de este artículo está disponible en PDF.

Keywords : Digoxin immune Fab, Digoxin toxicity, Expert consensus


Esquema


 Funding: Financial support for conduct of the study was provided by BTG Pharmaceuticals. The sponsor did not have a role in study design, collection, analysis and interpretation of data, or in the decision to submit.
 Conflict of interest: All authors report receiving consulting fees from BTG Pharmaceuticals for participating in this project. There are no other relevant conflicts of interest to declare. JBH, SW, RZ, MWR and PJH report a relationship with BTG plc that includes: consulting or advisory and non-financial support. The honoraria were provided solely for this project. Administrative support was provided by Synchrony Communications via BTG.
 Authorship: JBH: Writing – review & editing, Writing – original draft, Project administration, Methodology, Formal analysis, Conceptualization; SW: Writing – review & editing, Writing – original draft, Methodology; RZ: Writing – review & editing, Methodology; MWR: Writing – review & editing, Writing – original draft, Methodology, Formal analysis; PJH: Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Formal analysis, Conceptualization.


© 2024  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 138 - N° 1

P. 25 - janvier 2025 Regresar al número
Artículo precedente Artículo precedente
  • Heads-Up! A Caregiver's Perspective on Lewy Body Dementia
  • Freda Spector Warrington
| Artículo siguiente Artículo siguiente
  • Evaluating Academic Physicians’ Bibliographies: Criteria and Fairness
  • Thomas J. Beckman

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.